Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Structure-Function Correlation With Optical Coherence Tomography-Derived Macular Thickness and Macular Microperimetry in Children, Adolescents, and Young Adults With Sickle Cell Disease.

Journal of vitreoretinal diseases·2026

Same author

Acute Macular Neuroretinopathy and Peripheral Retinal Abnormalities in a Patient With Adams-Oliver Syndrome.

Journal of vitreoretinal diseases·2026

Same author

Systemic Statin Use and Reduced Risk of Repeat Retinal Detachment Repair: A Retrospective Cohort Study.

Ophthalmology. Retina·2026

Same author

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection vs Laser.

American journal of ophthalmology·2026

Same author

Systemic Anemia and the Risk of Diabetic Macular Edema and Anti-VEGF Injections.

Ophthalmology. Retina·2026

Same author

REPLY.

Ophthalmology·2026

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation.

Owais Fazal¹, Asad Loya², Jawad Muayad³

¹From the Department of Ophthalmology (O.F., D.D.B., C.C., N.A.P.), Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA; Harvard Medical School (O.F.), Boston, Massachusetts, USA.

American Journal of Ophthalmology

|June 23, 2026

Summary

Levodopa ± carbidopa use was linked to a lower risk of developing neovascular age-related macular degeneration (nAMD). Dopamine receptor D2 agonists did not show a significant association with nAMD risk in this study.

Related Experiment Videos

Last Updated: Jun 25, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Area of Science:

Ophthalmology
Neuroscience
Pharmacology

Background:

Age-related macular degeneration (AMD) is a primary cause of vision loss globally.
Dopaminergic pathways are increasingly recognized for their potential role in AMD progression.

Purpose of the Study:

To investigate the association between levodopa ± carbidopa or dopamine receptor D2 (DRD2) agonists and the risk of conversion to neovascular AMD (nAMD).

Main Methods:

A population-based clinical cohort study using the TriNetX U.S. Collaborative Network.
Retrospective analysis emulating target trials comparing new users of levodopa ± carbidopa or DRD2 agonists against pantoprazole or gabapentin.
1:1 propensity score matching was used to control for confounding factors, with the primary outcome being the 3-year risk of conversion to nAMD.

Main Results:

Levodopa ± carbidopa use was associated with a reduced 3-year risk of conversion to nAMD compared to both pantoprazole (HR 0.67) and gabapentin (HR 0.69).
No significant association was found between DRD2 agonists use and the 3-year risk of conversion to nAMD when compared to pantoprazole (HR 0.81) or gabapentin (HR 0.92).

Conclusions:

Levodopa ± carbidopa use demonstrated a protective association against the progression to nAMD.
DRD2 agonists did not show a significant effect on nAMD progression risk.
These findings suggest a role for dopaminergic signaling in AMD progression, meriting further research.